optometryadvisor1h
Dementia Death Rates in US Older Adults Fluctuated From 2018 to 2022
Age-adjusted dementia deaths rates were stable between 2018 and 2019, then increased in 2020 and decreased slightly in 2022.
Organically Human on MSN5h
13 Early Signs of Alzheimer's You Shouldn't Ignore
While there is no cure, recognizing the early signs allows for proactive management, enabling individuals and families to ...
Alzheimer’s Brain Changes Defy Standard Patterns, Study Finds
A new study finds that brain shrinkage in Alzheimer’s disease varies greatly among individuals, with distinct patterns rather than a uniform progression. These findings may pave the way for ...
Neuroscience News1d
Unique Brain Plaques Linked to Alzheimer’s Mutation Decoded
Researchers have identified the structure of amyloid beta fibrils linked to a rare inherited form of Alzheimer’s disease ...
Beyond Plaques and Tangles: Scientists Discover Key to Halting Brain Damage in Alzheimer’s
Researchers discover protective pathway against Alzheimer's in mice Alzheimer's disease is marked by the gradual degeneration ...
verywellhealth3d
What’s the Difference Between Dementia and Alzheimer’s?
Dementia describes symptoms like memory loss in multiple diseases, and Alzheimer’s is the most common form. Here are the key ...
Antipsychotic Drugs in Nursing Homes
The use and ethics of antipsychotic drugs in nursing homes is an ongoing discussion. Learn why these medications are ...
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...
CHMP issues positive recommendation for approval of lecanemab in the EU
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announces that EMA's Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation regarding BioArctic's partner Eisai ...
Biogen Inc.: Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...
University of Delaware5d
New Alzheimer’s insights
Too often, people learn they have Alzheimer’s disease (AD) when it’s too late. The changes in the brain that lead to AD ...
INmune Bio, Inc.: INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimer's Disease
INmune Bio, Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage inflammation and immunology company focused on developing treatments that harness ...